Macrogenics (MGNX) Depreciation & Amortization (CF) (2012 - 2026)
Macrogenics (MGNX) reported Depreciation & Amortization (CF) of $1.7 million for Q1 2026, down 4.74% year-over-year from $1.8 million in Q1 2025, and down 1.06% quarter-over-quarter from $1.7 million in Q4 2025.
Macrogenics (MGNX) Depreciation & Amortization (CF) (2012 - 2026) Analysis & Trends
Macrogenics (MGNX) has 15 years of Depreciation & Amortization (CF) data on file, last reported at $1.7 million in Q1 2026.
- Depreciation & Amortization (CF) for Q1 2026 came in at $1.7 million, down 4.74% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.1 million (down 5.11% YoY), and the FY2025 annual result was $7.2 million, down 4.88% from the prior year.
- Depreciation & Amortization (CF) declined to $1.7 million in Q1 2026 per MGNX's latest filing, from $1.7 million in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $3.2 million in Q4 2022 and troughed at $1.7 million in Q1 2026.
- A 5-year average of $2.2 million and a median of $1.9 million in 2025 frame the typical range for Depreciation & Amortization (CF).
- The sharpest annual moves came in 2022 and 2023: Depreciation & Amortization (CF) grew 9.45% in 2022, then plunged 41.19% in 2023.
- A 5-year view of Depreciation & Amortization (CF) shows it stood at $3.2 million in 2022, then slumped by 41.19% to $1.9 million in 2023, then rose by 8.05% to $2.1 million in 2024, then declined by 16.95% to $1.7 million in 2025, then decreased by 1.06% to $1.7 million in 2026.
- Business Quant data shows MGNX's Depreciation & Amortization (CF) at $1.7 million in Q1 2026, $1.7 million in Q4 2025, and $1.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1,395.22 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 429,663.65 |
| 10 | Macrogenics | 260.14 Mn | 193.63 Mn | - | 1.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.69 Mn |
| Mar 31, 2026 | 1.69 Mn |
| Dec 31, 2025 | 1.71 Mn |
| Dec 31, 2025 | 1.71 Mn |
| Sep 30, 2025 | 1.79 Mn |
| Sep 30, 2025 | 1.79 Mn |
| Jun 30, 2025 | 1.91 Mn |
| Jun 30, 2025 | 1.91 Mn |
| Mar 31, 2025 | 1.77 Mn |
| Mar 31, 2025 | 1.77 Mn |
| Dec 31, 2024 | 2.05 Mn |
| Dec 31, 2024 | 2.05 Mn |
| Sep 30, 2024 | 1.84 Mn |
| Sep 30, 2024 | 1.84 Mn |
| Jun 30, 2024 | 1.81 Mn |
| Jun 30, 2024 | 1.81 Mn |
| Mar 31, 2024 | 1.84 Mn |
| Mar 31, 2024 | 1.84 Mn |
| Dec 31, 2023 | 1.90 Mn |
| Dec 31, 2023 | 1.90 Mn |